SAN DIEGO, June 27, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 2,415,000 shares of its common stock at a public offering price of $97.00 per s… […]
SAN DIEGO, June 25, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 2,100,000 shares of its common stock at a price to the public of $97.00 per share. The aggregate gros… […]
SAN DIEGO and PENNINGTON, N.J., May 21, 2019 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced that it intends to o… […]
SAN DIEGO, March 15, 2019 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes o… […]
SAN DIEGO, Feb. 14, 2019 /PRNewswire/ — Cibus, a leader in advanced plant-breeding technologies, today announced it has postponed plans for an initial public offering.
“We elected to postpone our offering given current market and technical conditi… […]
SAN DIEGO, Feb. 8, 2019 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 6,250,000 shares of its co… […]
SAN DIEGO, Jan. 22, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 1,854,838 shares of its common stock at a public offering price of $62.00 per s… […]
SAN DIEGO, Jan. 18, 2019 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of… […]
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, $75.0 million of shares of its common stock in an underwritten public offeri… […]
SAN DIEGO, Dec. 11, 2018 /PRNewswire/ — Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All shares … […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
